Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of atorvastatin in treating patients with ulcerative
colitis who have a dominant-negative missense P53 mutation and are at risk of developing
large intestinal cancer. Patients with ulcerative colitis are known to have an increased risk
of developing large intestinal cancer. Better ways to control ulcerative colitis and more
knowledge about how to prevent colon cancer are needed. Atorvastatin is a drug used to lower
the amount of cholesterol in the blood and to prevent stroke, heart attack, and angina (chest
pain). It blocks an enzyme that helps make cholesterol in the body. It also causes an
increase in the breakdown of cholesterol. The information gained from this study may help
doctors learn more about atorvastatin as an agent in cancer prevention, and may help to
improve public health.